statistiche ricercatore

Continente	#
NA - Nord America	500
AS - Asia	334
EU - Europa	285
SA - Sud America	50
AF - Africa	26
Continente sconosciuto - Info sul continente non disponibili	15
OC - Oceania	1
Totale	1.211

Nazione	#
US - Stati Uniti d'America	472
CN - Cina	124
IE - Irlanda	99
SG - Singapore	78
RU - Federazione Russa	47
DE - Germania	44
VN - Vietnam	44
BR - Brasile	42
HK - Hong Kong	42
FI - Finlandia	22
CA - Canada	21
IT - Italia	20
ZA - Sudafrica	15
IN - India	14
FR - Francia	13
SE - Svezia	8
GB - Regno Unito	7
BD - Bangladesh	6
MX - Messico	5
NL - Olanda	5
PL - Polonia	4
AE - Emirati Arabi Uniti	3
AT - Austria	3
ES - Italia	3
IQ - Iraq	3
JP - Giappone	3
KE - Kenya	3
MA - Marocco	3
AR - Argentina	2
BG - Bulgaria	2
CO - Colombia	2
ID - Indonesia	2
MY - Malesia	2
PE - Perù	2
PH - Filippine	2
PK - Pakistan	2
AU - Australia	1
BA - Bosnia-Erzegovina	1
CL - Cile	1
ET - Etiopia	1
GA - Gabon	1
GD - Grenada	1
GE - Georgia	1
GR - Grecia	1
IL - Israele	1
JO - Giordania	1
LB - Libano	1
LK - Sri Lanka	1
LT - Lituania	1
LV - Lettonia	1
MD - Moldavia	1
MU - Mauritius	1
NI - Nicaragua	1
QA - Qatar	1
RO - Romania	1
SA - Arabia Saudita	1
SC - Seychelles	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
TM - Turkmenistan	1
UA - Ucraina	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.196

Nome	#
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms	156
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin	131
Diagnosis and management of prefibrotic myelofibrosis.	113
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.	108
Facing erythrocytosis: Results of an international physician survey.	103
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.	101
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.	93
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.	93
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms	81
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera.	80
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.	80
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.	72
Totale	1.211

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	62	0	0	10	2	3	3	1	3	3	1	9	27
2022/2023	210	24	12	5	9	15	15	0	13	106	4	6	1
2023/2024	105	16	21	6	5	6	35	0	8	3	1	2	2
2024/2025	229	8	14	6	1	0	16	14	18	66	5	32	49
2025/2026	493	41	15	47	49	50	21	117	30	58	30	11	24
2026/2027	19	6	13	0	0	0	0	0	0	0	0	0	0
Totale													1.211